Risk factors for transport-related problem behaviors in horses: A New Zealand survey

Transport-related problem behaviors (TRPBs) are common in horses and can cause injury to both the horses and their handlers. This study aimed to identify possible risk factors for TRPBs to inform approaches to mitigate TRPBs incidence and enhance horse welfare. An online cross-sectional survey was conducted to explore the prevalence of TRPBs and their association with human-, training-and transport management-related factors in New Zealand. The survey generated 1124 valid responses that were analyzed using descriptive statistics, and logistic regression analyses. Having at least one horse with TRPB was reported by 249/1124 (22.2%) respondents during the two previous years. Of these, 21/249 (8.4%) occurred during pre-loading, 78/249 (31.3%) during loading, 132/249 (53.0%) while travelling, and 18/249 (7.3%) during unloading. Our findings indicate that the use of negative reinforcement and positive punishment as training methods, using a whip or food for loading, and travelling in a straight load trailer/float while offering food were associated with a higher likelihood of TRPBs. Cross-sectional studies cannot determine causality and findings should be interpreted with caution, and evaluated in further experimental studies. The authors suggest that education on appropriate training methods for transport, and vehicle selection may mitigate the risk for TRPBs in horses

Microcraters in aluminum foils exposed by Stardust

We will present preliminary results on the nature and size frequency distribution of microcraters that formed in aluminum foils during the flyby of comet Wild 2 by the Stardust spacecraft

Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment

Pulmonary alveolar microlithiasis (PAM) is a rare, autosomal recessive lung disorder associated with progressive accumulation of calcium phosphate microliths. Inactivating mutations in SLC34A2, which encodes the NPT2b sodiumdependent phosphate cotransporter, has been proposed as a cause of PAM.Weshow that epithelial deletion ofNpt2b in mice results in a progressive pulmonary process characterized by diffuse alveolar microlith accumulation, radiographic opacification, restrictive physiology, inflammation, fibrosis, and an unexpected alveolar phospholipidosis. Cytokine and surfactant protein elevations in the alveolar lavage and serum of PAM mice and confirmed in serum from PAM patients identify serum MCP-1 (monocyte chemotactic protein 1) and SP-D (surfactant protein D) as potential biomarkers.Microliths introduced by adoptive transfer into the lungs of wild-typemice produce markedmacrophagerich inflammation and elevation of serum MCP-1 that peaks at 1 week and resolves at 1 month, concomitant with clearance of stones. Microliths isolated by bronchoalveolar lavage readily dissolve in EDTA, and therapeutic wholelung EDTA lavage reduces the burden of stones in the lungs. A low-phosphate diet prevents microlith formation in young animals and reduces lung injury on the basis of reduction in serum SP-D. The burden of pulmonary calcium deposits in established PAM is also diminished within 4 weeks by a low-phosphate diet challenge. These data support a causative role for Npt2b in the pathogenesis of PAM and the use of the PAMmouse model as a preclinical platform for the development of biomarkers and therapeutic strategies

Relativistic transition wavelenghts and probabilities for spectral lines of Ne II

Transition wavelengths and probabilities for several 2p4 3p - 2p4 3s and 2p4 3d - 2p4 3p lines in fuorine-like neon ion (NeII) have been calculated within the multiconfiguration Dirac-Fock (MCDF) method with quantum electrodynamics (QED) corrections. The results are compared with all existing experimental and theoretical data

Spatial Stability of Incompressible Attachment-Line Flow

Linear stability analysis of incompressible attachment-line flow is presented within the spatial framework. The system of perturbation equations is solved using spectral collocation. This system has been solved in the past using the temporal approach and the current results are shown to be in excellent agreement with neutral temporal calculations. Results amenable to direct comparison with experiments are then presented for the case of zero suction. The global solution method utilized for solving the eigenproblem yields, aside from the well-understood primary mode, the full spectrum of least-damped waves. Of those, a new mode, well separated from the continuous spectrum is singled out and discussed. Further, relaxation of the condition of decaying perturbations in the far-field results in the appearance of sinusoidal modes akin to those found in the classical Orr-Sommerfeld problem. Finally, the continuous spectrum is demonstrated to be amenable to asymptotic analysis. Expressions are derived for the location, in parameter space, of the continuous spectrum, as well as for the limiting cases of practical interest. In the large Reynolds number limit the continuous spectrum is demonstrated to be identical to that of the Orr-Sommerfeld equation

A SLUGGS and Gemini/GMOS combined study of the elliptical galaxy M60: wide-field photometry and kinematics of the globular cluster system

We present new wide-field photometry and spectroscopy of the globular clusters (GCs) around NGC 4649 (M60), the third brightest galaxy in the Virgo cluster. Imaging of NGC 4649 was assembled from a recently obtained Hubble Space Telescope/Advanced Camera for Surveys mosaic, and new Subaru/Suprime-Cam and archival Canada–France–Hawaii Telescope/MegaCam data. About 1200 sources were followed up spectroscopically using combined observations from three multi-object spectrographs: Keck/Deep Imaging Multi-Object Spectrograph, Gemini/Gemini Multi-Object Spectrograph and Multiple Mirror Telescope/Hectospec. We confirm 431 unique GCs belonging to NGC 4649, a factor of 3.5 larger than previous data sets and with a factor of 3 improvement in velocity precision. We confirm significant GC colour bimodality and find that the red GCs are more centrally concentrated, while the blue GCs are more spatially extended. We infer negative GC colour gradients in the innermost 20 kpc and flat gradients out to large radii. Rotation is detected along the galaxy major axis for all tracers: blue GCs, red GCs, galaxy stars and planetary nebulae. We compare the observed properties of NGC 4649 with galaxy formation models. We find that formation via a major merger between two gas-poor galaxies, followed by satellite accretion, can consistently reproduce the observations of NGC 4649 at different radii. We find no strong evidence to support an interaction between NGC 4649 and the neighbouring spiral galaxy NGC 4647. We identify interesting GC kinematic features in our data, such as counter-rotating subgroups and bumpy kinematic profiles, which encode more clues about the formation history of NGC 4649

A First Search for coincident Gravitational Waves and High Energy Neutrinos using LIGO, Virgo and ANTARES data from 2007

We present the results of the first search for gravitational wave bursts associated with high energy neutrinos. Together, these messengers could reveal new, hidden sources that are not observed by conventional photon astronomy, particularly at high energy. Our search uses neutrinos detected by the underwater neutrino telescope ANTARES in its 5 line configuration during the period January - September 2007, which coincided with the fifth and first science runs of LIGO and Virgo, respectively. The LIGO-Virgo data were analysed for candidate gravitational-wave signals coincident in time and direction with the neutrino events. No significant coincident events were observed. We place limits on the density of joint high energy neutrino - gravitational wave emission events in the local universe, and compare them with densities of merger and core-collapse events.Comment: 19 pages, 8 figures, science summary page at http://www.ligo.org/science/Publication-S5LV_ANTARES/index.php. Public access area to figures, tables at https://dcc.ligo.org/cgi-bin/DocDB/ShowDocument?docid=p120000

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

BACKGROUND Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known. METHODS We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia. Patients 10 to 17 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who had an LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) or placebo. The primary end point was the percent change in LDL cholesterol level from baseline to week 24; key secondary end points were the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the absolute change in LDL cholesterol level from baseline to week 24. RESULTS A total of 157 patients underwent randomization and received evolocumab (104 patients) or placebo (53 patients). At week 24, the mean percent change from baseline in LDL cholesterol level was −44.5% in the evolocumab group and −6.2% in the placebo group, for a difference of −38.3 percentage points (P<0.001). The absolute change in the LDL cholesterol level was −77.5 mg per deciliter (−2.0 mmol per liter) in the evolocumab group and −9.0 mg per deciliter (−0.2 mmol per liter) in the placebo group, for a difference of −68.6 mg per deciliter (−1.8 mmol per liter) (P<0.001). Results for all secondary lipid variables were significantly better with evolocumab than with placebo. The incidence of adverse events that occurred during the treatment period was similar in the evolocumab and placebo groups. CONCLUSIONS In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables. (Funded by Amgen; HAUSER-RCT ClinicalTrials.gov number, NCT02392559. opens in new tab.

Ethnic profiling in the Netherlands? A reflection on expanding preventive powers, ethnic profiling and a changing social and political context

Criminal Justice: Legitimacy, accountability, and effectivit